Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03363321 · ClinicalTrials.gov registry record · Phase 2
PF-06741086 Long-term Treatment in Severe Hemophilia
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT03363321 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 20 participants.
The verdict
NCT03363321, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety, tolerability and efficacy of long-term treatment with PF-06741086 in subjects with severe hemophilia who participated in the 3-month Phase 1b/2 B7841002 study. Additionally, de novo subjects will be recruited into this study.
Interventions
- BIOLOGICAL PF-06741086
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-05-30 |
| Est. Completion | 2020-08-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03363321
The ClinicalTrials.gov registry entry for NCT03363321 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-06741086 is the first listed.
NCT03363321 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03363321 about?
NCT03363321 is a clinical study titled "PF-06741086 Long-term Treatment in Severe Hemophilia". This study is designed to evaluate the safety, tolerability and efficacy of long-term treatment with PF-06741086 in subjects with severe hemophilia who participated in the 3-month Phase 1b/2 B7841002 study. Additionally, de novo subjects will be recruited into this study.
What is the current status of trial NCT03363321?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2018-05-30. Estimated completion is 2020-08-05.
What interventions are being tested in trial NCT03363321?
The interventions under investigation include: PF-06741086 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03363321?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.